LOMEFLOXACIN, ASPARTATE

The main ingredient of this product is lomefloxacin aspartate, and its chemical name is: 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid aspartate

1Theophylline: In clinical studies of long-term use of theophylline, lomefloxacin had no significant effect on theophylline concentration. 2Caffeine: 200 mg of caffeine was given to healthy volunteers who had reached steady-state lomefloxacin blood concentrations, which did not cause statistically significant differences, and did not cause changes in the pharmacokinetic parameters of caffeine and its main metabolites. 3Cimetidine: Cimetidine can interfere with the elimination of other quinolone drugs, resulting in an increase in half-life and AUC. The interaction between cimetidine and lomefloxacin has not been studied. 4Cyclosporin: Cyclosporin and other quinolones can increase the serum concentration of cyclosporin. The interaction between cyclosporin and lomefloxacin has not been studied. 5Omeprazole: Multiple doses of omeprazole followed by a single dose of lomefloxacin did not cause significant changes in the pharmacokinetic parameters of lomefloxacin (AUC, Cmax, tmax), and the pharmacokinetic changes of omeprazole have not been studied. 6 Phenytoin sodium: When phenytoin sodium extended-release capsules were co-administered with lomefloxacin for 5 days, there was no significant change in the pharmacokinetic parameters of phenytoin sodium, AUC, Cmax, Cmin or tmax. Lomefloxacin may not have a significant effect on the metabolism of phenytoin. 7 Terfenadine: In a steady-state study of 28 healthy men, the co-administration of terfenadine and lomefloxacin did not significantly change the heart rhythm or QT interval, the pharmacokinetics of terfenadine or lomefloxacin. 8 Warfarin: Quinolones can enhance the effects of the coagulation drug warfarin or its derivatives. When these drugs are used in combination, the prothrombin time or other coagulation tests should be closely monitored. However, when warfarin and lomefloxacin were co-administered under steady-state conditions, there was no significant change in the clotting time ratio or the pharmacokinetics of warfarin enantiomers. 9 Antacids and sucralfate: Antacids and sucralfate containing magnesium or aluminum, as well as preparations containing divalent and trivalent ions such as dideoxycreatinine, can form complexes with lomefloxacin and interfere with the bioavailability of lomefloxacin. 10 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity.

The main ingredient of this product is lomefloxacin aspartate, and its chemical name is: 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid aspartate

1Theophylline: In clinical studies of long-term use of theophylline, lomefloxacin had no significant effect on theophylline concentration. 2Caffeine: 200 mg of caffeine was given to healthy volunteers who had reached steady-state lomefloxacin blood concentrations, which did not cause statistically significant differences, and did not cause changes in the pharmacokinetic parameters of caffeine and its main metabolites. 3Cimetidine: Cimetidine can interfere with the elimination of other quinolone drugs, resulting in an increase in half-life and AUC. The interaction between cimetidine and lomefloxacin has not been studied. 4Cyclosporin: Cyclosporin and other quinolones can increase the serum concentration of cyclosporin. The interaction between cyclosporin and lomefloxacin has not been studied. 5Omeprazole: Multiple doses of omeprazole followed by a single dose of lomefloxacin did not cause significant changes in the pharmacokinetic parameters of lomefloxacin (AUC, Cmax, tmax), and the pharmacokinetic changes of omeprazole have not been studied. 6 Phenytoin sodium: When phenytoin sodium extended-release capsules were co-administered with lomefloxacin for 5 days, there was no significant change in the pharmacokinetic parameters of phenytoin sodium, AUC, Cmax, Cmin or tmax. Lomefloxacin may not have a significant effect on the metabolism of phenytoin. 7 Terfenadine: In a steady-state study of 28 healthy men, the co-administration of terfenadine and lomefloxacin did not significantly change the heart rhythm or QT interval, the pharmacokinetics of terfenadine or lomefloxacin. 8 Warfarin: Quinolones can enhance the effects of the coagulation drug warfarin or its derivatives. When these drugs are used in combination, the prothrombin time or other coagulation tests should be closely monitored. However, when warfarin and lomefloxacin were co-administered under steady-state conditions, there was no significant change in the clotting time ratio or the pharmacokinetics of warfarin enantiomers. 9 Antacids and sucralfate: Antacids and sucralfate containing magnesium or aluminum, as well as preparations containing divalent and trivalent ions such as dideoxycreatinine, can form complexes with lomefloxacin and interfere with the bioavailability of lomefloxacin. 10 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity.

The main ingredient of this product is lomefloxacin aspartate, and its chemical name is: 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid aspartate

1Theophylline: In clinical studies of long-term use of theophylline, lomefloxacin had no significant effect on theophylline concentration. 2Caffeine: 200 mg of caffeine was given to healthy volunteers who had reached steady-state lomefloxacin blood concentrations, which did not cause statistically significant differences, and did not cause changes in the pharmacokinetic parameters of caffeine and its main metabolites. 3Cimetidine: Cimetidine can interfere with the elimination of other quinolone drugs, resulting in an increase in half-life and AUC. The interaction between cimetidine and lomefloxacin has not been studied. 4Cyclosporin: Cyclosporin and other quinolones can increase the serum concentration of cyclosporin. The interaction between cyclosporin and lomefloxacin has not been studied. 5Omeprazole: Multiple doses of omeprazole followed by a single dose of lomefloxacin did not cause significant changes in the pharmacokinetic parameters of lomefloxacin (AUC, Cmax, tmax), and the pharmacokinetic changes of omeprazole have not been studied. 6 Phenytoin sodium: When phenytoin sodium extended-release capsules were co-administered with lomefloxacin for 5 days, there was no significant change in the pharmacokinetic parameters of phenytoin sodium, AUC, Cmax, Cmin or tmax. Lomefloxacin may not have a significant effect on the metabolism of phenytoin. 7 Terfenadine: In a steady-state study of 28 healthy men, the co-administration of terfenadine and lomefloxacin did not significantly change the heart rhythm or QT interval, the pharmacokinetics of terfenadine or lomefloxacin. 8 Warfarin: Quinolones can enhance the effects of the coagulation drug warfarin or its derivatives. When these drugs are used in combination, the prothrombin time or other coagulation tests should be closely monitored. However, when warfarin and lomefloxacin were co-administered under steady-state conditions, there was no significant change in the clotting time ratio or the pharmacokinetics of warfarin enantiomers. 9 Antacids and sucralfate: Antacids and sucralfate containing magnesium or aluminum, as well as preparations containing divalent and trivalent ions such as dideoxycreatinine, can form complexes with lomefloxacin and interfere with the bioavailability of lomefloxacin. 10 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity.